期刊
AAPS PHARMSCITECH
卷 15, 期 5, 页码 1163-1171出版社
SPRINGER
DOI: 10.1208/s12249-014-0142-7
关键词
drug delivery; mesoporous silica; nanoparticles
资金
- NCI NIH HHS [P30 CA036727] Funding Source: Medline
Mesoporous silica nanoparticles (MSNs) have been proposed as drug delivery devices for approximately 15 years. The history of in vitro studies has been promising, demonstrating that MSNs have the capability for stimulus-responsive controlled release, good cellular uptake, cell specific targeting, and the ability to carry a variety of cargoes from hydrophobic drug molecules to imaging agents. However, the translation of the in vitro findings to in vivo conditions has been slow. Herein, we review the current state-of-the-art in the use of MSN for systemic drug delivery in vivo and provide critical insight into the future of MSNs as systemic drug delivery devices and directions that should be undertaken to improve their practicality.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据